Cell cycle dysregulation is a hallmark of cancer that promotes eccessive cell division. Cyclin-
dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) are key molecules in …

CDK4/6 inhibitors have become game-changers in the treatment of estrogen receptor-
positive (ER+) breast cancer, and in combination with endocrine therapy are the standard of …

Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in
a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following …

Oral selective estrogen receptor degraders (SERD) could become the backbone of
endocrine therapy (ET) for estrogen receptor–positive (ER+) breast cancer, as they achieve …

Endocrine therapy (ET) in combination with CDK4/6 inhibition is routinely used as first-line
treatment for HR+/HER2− metastatic breast cancer (MBC) patients. However, 30–40% of …

The emergence of CDK4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, has
revolutionized the treatment landscape for hormone receptor-positive breast cancer. These …

CDK4/6 are important regulators of cell cycle and their inhibitors have been approved as
anti-cancer drugs. Here, we report a STING-dependent anti-tumor immune mechanism …

Background Intra-tumoral heterogeneity (ITH) is a distinguished hallmark of cancer, and
cancer stem cells (CSCs) contribute to this malignant characteristic. Therefore, it is of great …

Background Mutations of the PIK3CA/AKT/mTOR axis are common events in metastatic
breast cancers (MBCs). This study was designed to evaluate the extent to which genetic …

Simple Summary Nowadays, the upfront treatment for patients facing a diagnosis of
advanced luminal breast cancer (BC) is a combination of endocrine therapy (ET) with an …